Compare VERX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERX | TRVI |
|---|---|---|
| Founded | 1978 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2020 | 2019 |
| Metric | VERX | TRVI |
|---|---|---|
| Price | $12.20 | $13.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $17.15 | ★ $28.18 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $748,444,000.00 | N/A |
| Revenue This Year | $10.51 | N/A |
| Revenue Next Year | $10.51 | N/A |
| P/E Ratio | $302.25 | ★ N/A |
| Revenue Growth | ★ 12.25 | N/A |
| 52 Week Low | $10.21 | $9.29 |
| 52 Week High | $26.54 | $20.22 |
| Indicator | VERX | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 22.34 |
| Support Level | $12.16 | $13.08 |
| Resistance Level | $13.56 | $13.55 |
| Average True Range (ATR) | 0.49 | 0.56 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 71.00 | 10.70 |
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.